 To follow longitudinally healthy and immune-compromised responses to pneumococcal vaccination, in 60 individuals towards the development of personalized medicine implementation minimum enrollments in 2 age categories: young adults18-25, older adults 55, within each category: 10 healthy, 10 asthma, 10 immune-compromised e.g. leukemia or autoimmune disorders. The approach will profile thousands of molecular components utilizing high-throughput technologies and integrate these data to obtain personalized immune response to vaccination. The study will provide insights into immune response mechanisms specific to asthmatics, immune compromised and healthy individuals, as well as in response to vaccination. Additionally the differences in dynamic response across the two age groups will be investigated. 